117 related articles for article (PubMed ID: 34941995)
41. Mix-and-match COVID vaccines trigger potent immune response.
Callaway E
Nature; 2021 May; 593(7860):491. PubMed ID: 34012131
[No Abstract] [Full Text] [Related]
42. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.
Singh H; Figliola MJ; Dawson MJ; Huls H; Olivares S; Switzer K; Mi T; Maiti S; Kebriaei P; Lee DA; Champlin RE; Cooper LJ
Cancer Res; 2011 May; 71(10):3516-27. PubMed ID: 21558388
[TBL] [Abstract][Full Text] [Related]
43. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
Schulz E; Hodl I; Forstner P; Hatzl S; Sareban N; Moritz M; Fessler J; Dreo B; Uhl B; Url C; Grisold AJ; Khalil M; Kleinhappl B; Enzinger C; Stradner MH; Greinix HT; Schlenke P; Steinmetz I
Front Immunol; 2021; 12():803742. PubMed ID: 34950155
[TBL] [Abstract][Full Text] [Related]
44. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
45. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y
Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527
[TBL] [Abstract][Full Text] [Related]
46. Immune Response after SARS-CoV-2 Vaccination in Kidney Transplant Patients.
Vaiciuniene R; Sitkauskiene B; Bumblyte IA; Dalinkeviciene E; Ziginskiene E; Bagdonas D; Augliene R; Petruliene K; Bagdziuniene I; Skarupskiene I; Stankuviene A; Sauseriene J; Macinskas S; Valius L
Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946272
[No Abstract] [Full Text] [Related]
47. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Ghione P; Gu JJ; Attwood K; Torka P; Goel S; Sundaram S; Mavis C; Johnson M; Thomas R; McWhite K; Darrall A; DeMarco J; Kostrewa J; Mohr A; Rivas L; Neiders M; Suresh L; Segal BH; Griffiths EA; Ramsperger V; Shen L; Hernandez-Ilizaliturri FJ
Blood; 2021 Sep; 138(9):811-814. PubMed ID: 34189565
[No Abstract] [Full Text] [Related]
48. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
Front Immunol; 2019; 10():2664. PubMed ID: 31798590
[TBL] [Abstract][Full Text] [Related]
49. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
50. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
[TBL] [Abstract][Full Text] [Related]
51. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
52. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
Quinti I; Locatelli F; Carsetti R
Front Immunol; 2021; 12():815404. PubMed ID: 35126372
[TBL] [Abstract][Full Text] [Related]
53. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
54. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
[TBL] [Abstract][Full Text] [Related]
55. Dominant CD8
Taus E; Hofmann C; Ibarrondo FJ; Hausner MA; Fulcher JA; Krogstad P; Ferbas KG; Tobin NH; Rimoin AW; Aldrovandi GM; Yang OO
Front Immunol; 2022; 13():835830. PubMed ID: 35273611
[TBL] [Abstract][Full Text] [Related]
56. Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress.
Zhao J; Wu M; Li Z; Su S; Wen Y; Zhang L; Li Y
Ann Hematol; 2020 Aug; 99(8):1681-1699. PubMed ID: 32388608
[TBL] [Abstract][Full Text] [Related]
57. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
58. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
59. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
